Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15607887 | 1.00 | MAPK1 (0.33) | MAPK1ATMALDH1A1BACE1ELANE | |
| SCHEMBL16367371 | 0.88 | KMT2A (0.35) | MAPK1ATMALDH1A1ELANEGAA | |
| SCHEMBL15607895 | 0.88 | KMT2A (0.35) | MAPK1ATMALDH1A1ELANEGAA | |
| SCHEMBL16367379 | 0.86 | MAPK1 (0.35) | MAPK1ATMALDH1A1ELANEGAA | |
| SCHEMBL15607856 | 0.84 | MAPK1 (0.34) | MAPK1ATMALDH1A1ELANECHRM1 | |
| SCHEMBL16367391 | 0.81 | KMT2A (0.38) | MAPK1ATMALDH1A1ELANEGAA | |
| SCHEMBL15607841 | 0.79 | KMT2A (0.36) | MAPK1ATMALDH1A1GAACHRM1 | |
| SCHEMBL15607837 | 0.78 | TK1 (0.32) | MAPK1ATML3MBTL1KMT2A | |
| SCHEMBL16367322 | 0.74 | MAPK1 (0.38) | MAPK1ATMALDH1A1CHRM1SMN1; SMN2 | |
| SCHEMBL16367351 | 0.74 | MAPK1 (0.38) | MAPK1ATMALDH1A1CHRM1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | CBR1, CBR3, BLVRB | MAPK1 3155/4885ATM 4802/4885ALDH1A1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.